SERA: the cash flow

MyFinsight

For the year ending 2025-12-31, SERA had -$99K decrease in cash & cash equivalents over the period. -$26,349K in free cash flow.

Cash Flow	2025-12-31
Revenue	81
Cost of revenue	164
Payroll related expenses	16,745
Consulting and professional fees	6,944
Stock-based compensation expense	5,110
Equipment, lab supplies, and facility expenses	1,527
Clinical studies and outside processing	1,579
Depreciation and amortization	824
Other segment items	3,692
Loss from operations	-36,504
Interest expense	9
Other income, net	4,585
Net loss	-31,928
Depreciation and amortization	940
Stock-based compensation	5,110
Non-cash lease expense	492
Non-cash investment income, net	-314
Other	5
Accounts receivable	-22
Other receivables	-19
Prepaid expenses and other assets	352
Accounts payable	-1,009
Accrued and other current liabilities	682
Deferred revenue	92
Net cash used in operating activities	-25,623
Purchases of marketable securities	87,612
Proceeds from maturities and sales of marketable securities	59,836
Purchases of property and equipment	726
Purchase of intangible assets	0
Net cash (used in) provided by investing activities	-28,502
Proceeds from public offering of common stock, net of issuance costs	53,610
Proceeds from exercise of stock options	507
Proceeds from employee stock purchase plan	103
Finance lease principal payments	194
Net cash provided by financing activities	54,026
Net (decrease) increase in cash and cash equivalents	-99
Cash and cash equivalents at beginning of period	4,043
Cash and cash equivalents at end of period	3,944

Unit: Thousand (K) dollars (except for numbers of shares and EPS).